TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder
Brief Summary: The purpose of this study is to determine whether vilazodone is effective in the treatmen of Posttraumatic Stress Disorder (PTSD)and co-morbid mild or more depression.


Options:
A: Arm Label: Treatment (Viibryd); Type: EXPERIMENTAL; Interventions: Drug: Treatment (Viibryd) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Treatment (Viibryd) | Intervention Type: DRUG; Name: Treatment (Viibryd); Assigned to Arm(s): Placebo, Treatment (Viibryd)
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: trauma-focused cognitive behavioural therapy | Arm Label: Drug; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Waiting list; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Drug: Sertraline, Behavioral: trauma-focused cognitive behavioural therapy | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Combination, Drug | Intervention Type: BEHAVIORAL; Name: trauma-focused cognitive behavioural therapy; Assigned to Arm(s): Combination, psychotherapy
D: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate, Drug: placebo control group | Arm Label: Placebo Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control group | Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: placebo control group; Assigned to Arm(s): Placebo Control group, Topiramate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Telehealth Intervention Combining Structured Self-Monitoring of Blood Glucose and Nurse Care Coordination Among People With Type 2 Diabetes Noninsulin-Treated
Brief Summary: Telehealth remote patient monitoring is a means of using communications technology - such as telephones, computers, and the Internet - to connect patients remotely with their healthcare team from their homes. The investigators hope to learn more about improving healthy behaviors and blood glucose among persons with diabetes using telehealth remote patient monitoring technology to connect directly with nurse care coordinators.

The purpose of this study is to evaluate a process for improving blood glucose and healthy behaviors among people with type 2 diabetes using telehealth remote patient monitoring technology with nurse care coordinators. Some of the people in this study will work with a nurse care coordinator who will review your blood glucose weekly and call you at home every month for 3 months, while some of the people in this study will simply receive their normal care. At the end of the study, every participant will be asked questions about how they feel about their health care.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home Telehealth with Behavioral Education Component | Intervention Type: BEHAVIORAL; Name: Home Telehealth with Behavioral Education Component; Assigned to Arm(s): Intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
C: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Control-usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention paired testing and remote monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose | Intervention Type: BEHAVIORAL; Name: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose; Assigned to Arm(s): Intervention paired testing and remote monitoring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Brief Summary: The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD


Options:
A: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amide | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Amide; Assigned to Arm(s): 2
C: Arm Label: A1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antidepressant + Placebo | Arm Label: A2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antidepressant + Aripiprazole | Arm Label: A3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antidepressant + Placebo; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Antidepressant + Aripiprazole; Assigned to Arm(s): A2
D: Arm Label: Placebo + ADT Lead-in; Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Cariprazine + ADT (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Continued Treatment); Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine + ADT (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in | Intervention Type: DRUG; Name: Antidepressant Therapy (ADT); Assigned to Arm(s): Cariprazine + ADT (Double-Blind), Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study
Brief Summary: The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.


Options:
A: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell
B: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells
C: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells
D: Arm Label: Mesenchymal stem cell treatment; Type: EXPERIMENTAL; Interventions: Other: Mesenchymal stem cell | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.


Options:
A: Arm Label: PLD 40 mg/m2 plus VTX-2337; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: VTX-2337 | Arm Label: PLD 40 mg/m2 plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: Placebo | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337, PLD 40 mg/m2 plus placebo | Intervention Type: DRUG; Name: VTX-2337; Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLD 40 mg/m2 plus placebo
B: Arm Label: carboplatin and doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: pegylated liposomal doxorubicin hydrochloride | Arm Label: carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): carboplatin, carboplatin and doxorubicin | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): carboplatin and doxorubicin
C: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
D: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.


Options:
A: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)
B: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
C: Arm Label: Paclitaxel & Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel & Carboplatin & Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Basilar Artery International Cooperation Study
Brief Summary: Rationale: Recently our study group reported the results of the Basilar Artery International Cooperation Study (BASICS), a prospective registry of patients with an acute symptomatic basilar artery occlusion (BAO). Our observations in the BASICS registry underscore that we continue to lack a proven treatment modality for patients with an acute BAO and that current clinical practice varies widely. Furthermore, the often-held assumption that intra-arterial thrombolysis (IAT) is superior to intravenous thrombolysis (IVT) in patients with an acute symptomatic BAO is challenged by our data. The BASICS registry was observational and has all the limitations of a non-randomised study. Interpretation of results is hampered by the lack of a standard treatment protocol for all patients who entered the study.

Objective: Evaluate the efficacy and safety of IAT in addition to best medical management (BMM) in patients with basilar artery occlusion.

Study design: Randomised, multi-centre, open label, controlled phase III, treatment trial.

Study population: Patients, aged 18 years and older, with CTA or MRA confirmed basilar occlusion.

Intervention: Patients will be randomised between BMM with additional IAT versus BMM alone. IAT has to be initiated within 6 hours from estimated time of BAO. If treated with as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO.

Main study parameters/endpoints: Favorable outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-3.


Options:
A: Arm Label: Intensive blood pressure management; Type: EXPERIMENTAL; Interventions: Other: Systolic blood pressure target < 130 mm Hg | Arm Label: Standard blood pressure management; Type: ACTIVE_COMPARATOR; Interventions: Other: Systolic blood pressure target < 185 mm Hg | Intervention Type: OTHER; Name: Systolic blood pressure target < 130 mm Hg; Assigned to Arm(s): Intensive blood pressure management | Intervention Type: OTHER; Name: Systolic blood pressure target < 185 mm Hg; Assigned to Arm(s): Standard blood pressure management
B: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intensive BP lowering | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intensive BP lowering; Assigned to Arm(s): Intervention group
D: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Basilar Artery International Cooperation Study
Brief Summary: Rationale: Recently our study group reported the results of the Basilar Artery International Cooperation Study (BASICS), a prospective registry of patients with an acute symptomatic basilar artery occlusion (BAO). Our observations in the BASICS registry underscore that we continue to lack a proven treatment modality for patients with an acute BAO and that current clinical practice varies widely. Furthermore, the often-held assumption that intra-arterial thrombolysis (IAT) is superior to intravenous thrombolysis (IVT) in patients with an acute symptomatic BAO is challenged by our data. The BASICS registry was observational and has all the limitations of a non-randomised study. Interpretation of results is hampered by the lack of a standard treatment protocol for all patients who entered the study.

Objective: Evaluate the efficacy and safety of IAT in addition to best medical management (BMM) in patients with basilar artery occlusion.

Study design: Randomised, multi-centre, open label, controlled phase III, treatment trial.

Study population: Patients, aged 18 years and older, with CTA or MRA confirmed basilar occlusion.

Intervention: Patients will be randomised between BMM with additional IAT versus BMM alone. IAT has to be initiated within 6 hours from estimated time of BAO. If treated with as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO.

Main study parameters/endpoints: Favorable outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-3.


Options:
A: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.
C: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: B